Nyxoah Reports First Quarter 2026 Financial and Operating Results
Rhea-AI Summary
Nyxoah (Nasdaq:Euronext: NYXH) reported Q1 2026 net revenue of €6.4 million, up from €1.1 million a year earlier. U.S. net revenue reached €4.3 million, a 25% sequential increase, with global net revenue up 13% sequentially.
Gross margin was 57%. Operating loss was €20.5 million. Cash and financial assets totaled €25.9 million, with a planned €13.8 million EIB loan draw in Q2. 2026 guidance includes €36–40 million global net revenue, 60–62% gross margin and €97–99 million operating expenses.
Positive
- Q1 2026 net revenue rose to €6.4 million from €1.1 million year-over-year
- U.S. net revenue €4.3 million in Q1 2026, 25% sequential growth
- Global net revenue €6.4 million, 13% sequential growth versus Q4 2025
- Q1 2026 gross profit €3.6 million with 57% gross margin
- Cash and financial assets €25.9 million plus expected €13.8 million EIB draw in Q2 2026
- 2026 worldwide net revenue guidance of €36–40 million
- 2026 gross margin guidance of 60–62%
- 2026 total operating expenses guided to €97–99 million; non-GAAP cash opex €88–90 million
- 207 surgeons trained and 91 active high-volume U.S. accounts by end of Q1 2026
- 100% approval rate on reviewed U.S. commercial payer prior-authorization submissions
Negative
- Q1 2026 operating loss €20.5 million, similar to €20.6 million in Q1 2025
- Q1 2026 gross margin declined to 57% from 62% in Q1 2025
- Cost of goods sold increased to €2.7 million from €0.4 million year-over-year
- Selling, general and administrative expenses rose to €15.4 million from €12.4 million
- Company remains dependent on external financing, planning a €13.8 million EIB loan draw in Q2 2026
News Market Reaction – NYXH
In the May 13 session, NYXH gained 0.33%, reflecting a mild positive market reaction. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Q4 2025 results | Positive | -0.3% | Reported strong Q4 and full-year 2025 revenue growth and initial U.S. rollout. |
| Jan 12 | Prelim Q4 2025 | Positive | +3.0% | Issued preliminary Q4 and FY 2025 results with strong growth guidance for Q1 2026. |
| Nov 13 | Q3 2025 results | Positive | -5.8% | Detailed Q3 revenue growth, first U.S. revenue, margin and sizeable operating loss. |
| Aug 18 | Q2 2025 results | Positive | -4.6% | Announced FDA approval of Genio system and strong Q2 revenue increase with higher losses. |
| Aug 11 | Prelim Q2 2025 | Positive | -5.4% | Released preliminary Q2 results, FDA approval update and higher operating expenses details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across prior 5 earnings-related releases, NYXH often saw negative next-day moves despite growth and approval milestones, with 4 divergences versus generally positive fundamentals.
Over the past few quarters, Nyxoah has transitioned from early Genio launch to broader U.S. commercialization following FDA approval in August 2025. Earnings releases highlighted rapid revenue growth (Q3 and Q4 2025) and surgeon/account build-out alongside sizable operating losses and expanding expenses. Preliminary and final Q4 2025 updates emphasized strong U.S. momentum and cash balances. Today’s Q1 2026 report extends that trajectory with higher revenue, detailed margin disclosure and full‑year guidance, reinforcing the commercialization ramp narrative.
Key Terms
obstructive sleep apnea medical
medicare regulatory
cpt codes regulatory
prior authorization regulatory
non-gaap financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
REGULATED INFORMATION
Nyxoah Reports First Quarter 2026 Financial and Operating Results
Strong Genio launch in the U.S. drove
Continued clarity around HGNS and Genio reimbursement in the U.S.
Mont-Saint-Guibert, Belgium – May 12, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2026.
Q1 2026 Financial and Operating Highlights
- Financials
- U.S. net revenue first quarter 2026 was
€4.3 million (gross revenue was€4.5 million ),25% sequential growth over net revenue fourth quarter 2025 - Global net revenue first quarter 2026 was
€6.4 million (gross revenue was€6.7 million ),13% sequential growth over net revenue fourth quarter 2025
- U.S. net revenue first quarter 2026 was
- Leading U.S. commercial indicators
- 62 new surgeons trained in Q1, bringing the total to 207 surgeons trained
- 34 new accounts activated in Q1, bringing the total to 91 active high-volume accounts
- 241 patients submitted under prior authorization and still pending at the end of Q1
- U.S. reimbursement landscape – further clarified
- Medicare issued new C-Codes covering Genio and clarified facility and physician payments
- Commercial payers continued reimbursement under existing CPT codes
100% prior-authorization approval obtained on reviewed submissions with commercial payers and WISeR program
- As of March 31, 2026, cash, cash equivalents and financial assets amounted to
€25.9 million . In the second quarter of 2026, the Company expects to draw€13.8 million from the second tranche of the European Investment Bank loan.
“Our first quarter revenue results reflect strong execution of our U.S. launch. The
Results for the Three Months Ended March 31, 2026
Revenue
Gross revenue for the first quarter of 2026 was
Cost of Goods Sold
Cost of goods sold was
Research and Development
For the first quarter of 2026, research and development expenses were
Selling, General and Administrative
For the first quarter of 2026, selling, general and administrative expenses were
Operating Loss
Total operating loss for the first quarter of 2026 was
Cash Position
Cash, cash equivalents and financial assets amounted to approximately
In the second quarter of 2026, the Company expects to draw
Financial Guidance for the Second Quarter of 2026 and Full Year 2026
- The Company expects U.S. net revenue for the second quarter of 2026 to grow sequentially by approximately 25
-30% over the first quarter of 2026. - The Company expects worldwide net revenue for the full year 2026 to be in the range of
€36 million to€40 million . - The Company expects the gross margin for the full year 2026 to be in the range of
60% to62% . - The Company expects total operating expenses for the full year 2026 to be in the range of
€97 million to€99 million . The Company expects non-GAAP cash operating expenses for the full year 2026 to be in the range of€88 million to€90 million . Non-GAAP cash operating expenses reflect expected total operating expenses less non-cash expenses such as depreciation, amortization, and share-based compensation.
Conference call and webcast presentation
Company management will host a conference call to discuss financial results on Tuesday, May 12, 2026, beginning at 10:30pm CET / 4:30pm ET.
A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q1 2026 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.
If you plan to ask a question, please use the following link: Nyxoah's Q1 2026 Earnings Call Q&A Link. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.
The archived webcast will be available for replay shortly after the close of the call.
Non-GAAP financial measures
This press release includes non-GAAP (Generally Accepted Accounting Principles) financial measures, including non-GAAP cash operating expenses. Non-GAAP cash operating expenses are calculated by excluding from GAAP certain operating expenses items, including depreciation, amortization, capitalized research and development expenses, impairment losses on intangible assets, and share-based compensation. These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these non-GAAP financial measures as measures of the Company's operating performance and for planning purposes, including the preparation of the Company's annual operating budget and financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. These non-GAAP financial measures should not be considered alternatives to, or superior to, any other performance measure derived in accordance with GAAP. They should not be construed to imply that the Company's future results will be unaffected by unusual or non-recurring items. The Company's definitions of non-GAAP cash operating expenses are not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited) (in thousands)
For the Three Months Ended March 31,
| 2026 | 2025 | |||
| Revenue | ||||
| Cost of goods sold | (2 734) | (406) | ||
| Gross profit | ||||
| Research and Development Expense | (8 804) | (8 989) | ||
| Selling, General and Administrative Expense | (15 374) | (12 392) | ||
| Other income | 40 | 84 | ||
| Operating loss for the period | ||||
| Financial income | 6 982 | 2 622 | ||
| Financial expense | (2 036) | (4 242) | ||
| Loss for the period before taxes | ||||
| Income taxes | (390) | (125) | ||
| Loss for the period | ||||
| Loss attributable to equity holders | ||||
| Other comprehensive loss | ||||
| Items that may be subsequently reclassified to profit or loss (net of tax) | ||||
| Currency translation differences | (309) | (2) | ||
| Total comprehensive loss for the year, net of tax | ||||
| Loss attributable to equity holders | ||||
| Basic Loss Per Share (in EUR) | ||||
| Diluted Loss Per Share (in EUR) |
| CONSOLIDATED STATEMENT OF FINANCIAL POSITION (unaudited) (in thousands) | |||||
| As at | |||||
| March 31 2026 | December 31 2025 | ||||
| ASSETS | |||||
| Non-current assets | |||||
| Property, plant and equipment | 3 930 | 4 052 | |||
| Intangible assets | 49 237 | 50 108 | |||
| Right of use assets | 2 061 | 1 293 | |||
| Deferred tax asset | 11 | 87 | |||
| Other long-term receivables | 1 793 | 1 718 | |||
| Current assets | |||||
| Inventory | 4 348 | 4 660 | |||
| Trade receivables | 6 325 | 5 254 | |||
| Contract assets | 243 | 261 | |||
| Other receivables | 2 645 | 2 209 | |||
| Other current assets | 1 071 | 828 | |||
| Financial assets | 13 000 | 18 000 | |||
| Cash and cash equivalents | 12 934 | 30 001 | |||
| Total assets | |||||
| EQUITY AND LIABILITIES | |||||
| Share capital and reserves | |||||
| Share capital | 6 511 | 6 505 | |||
| Share premium | 337 242 | 335 134 | |||
| Share based payment reserve | 13 031 | 12 395 | |||
| Other comprehensive income | 815 | 1 124 | |||
| Retained loss | (321 728) | (306 029) | |||
| Total equity attributable to shareholders | |||||
| LIABILITIES | |||||
| Non-current liabilities | |||||
| Financial debt | 17 435 | 17 670 | |||
| Lease liability | 1 453 | 637 | |||
| Provisions | 1 039 | 1 396 | |||
| Deferred tax liability | 34 | − | |||
| Contract liability | 709 | 681 | |||
| Current liabilities | |||||
| Financial debt | 16 471 | 22 990 | |||
| Lease liability | 721 | 779 | |||
| Trade payables | 12 638 | 13 727 | |||
| Current tax liability | 4 355 | 3 939 | |||
| Contract liability | 1 120 | 894 | |||
| Other liabilities | 5 752 | 6 629 | |||
| Total liabilities | |||||
| Total equity and liabilities | |||||
Non-GAAP Financial Measures
The following tables contain a reconciliation of GAAP operating expenses to non-GAAP cash operating expenses for the three months ended March 31, 2026 and 2025, respectively.
| For the Three Months Ended March 31, | ||
| Unaudited – In thousands | 2026 | 2025 |
| GAAP R&D Operating Expenses | ||
| Depreciation and amortization | (1,276) | (411) |
| Impairment of intangibles | - | - |
| Share-based compensation | (78) | (310) |
| Capitalized R&D | 159 | 864 |
| Non-GAAP Cash R&D Operating Expenses | ||
| GAAP SG&A Operating Expenses | | |
| Depreciation | (440) | (363) |
| Share-based compensation | (803) | (1,665) |
| Non-GAAP Cash SG&A Operating Expenses | | |
Contacts:
Nyxoah
John Landry, CFO
IR@nyxoah.com
Rémi Renard
Head of Investor Relations & Corporate Communication
IR@nyxoah.com
Attachment
